Since completing my fellowship in August 1997, one of my research efforts had been the implementation of a dose individualization program with the adult and pediatric stem cell transplant programs here at MD Anderson Cancer Center with our Stem Cell Transplant (SCT) group in the use of high-dose busulfan in many SCT preparative regimen.. I led the development of the cancer center’s phase I/II research unit and was the director of the Clinical and Translation Research Center from 1997 until 2001 which I took from 1 room to a 10-room unit. Another area in which I have a particular interest is evaluation of interactions between two or more medications in individual patients. In an attempt to better define and understand these interactions between varieties of chemotherapeutic agents, preclinical experiments are done in both in-vitro and in-vivo models. Especially with novel molecular targeting agents, these sequence-specific experiments are designed to take advantage of the mechanism of activity of the individual agent. Once these mechanistic and results are validated, a potential is to bring these compound(s) into the clinic. Over the last several years, I have been collaborating with many of our faculty to develop and validate potential blood-based biomarker(s) of lung and head & neck cancers. This work has led us to identify several potential groups of blood-based markers correlating with therapeutic response or resistance. Additionally, current research has also focused on isolation and identification of molecular alterations from these rare circulating tumor cells and tumor DNA. As a part of our team lung cancer moon shot effort, I am leading the cell line drug screening; i.e., "re-purposing" old drugs for potentially new treatment for our patients with lung cancer.